Received Feb 10, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTPPVHBHPB | DTAP+IPV+HIB+HEPB (VAXELIS) | MSP VACCINE COMPANY | UNK | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| RVX | ROTAVIRUS (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | — | — |
No additional AE; FBE calling on behalf of Physician with a report of an adverse event regarding GARDASIL 9. FBE stated that during a routine vaccination appointment today, 2/5/2026, a 6-month-old male patient was inadvertently administered a dose of GARDASIL 9 in ad; This spontaneous report was received from a physician and refers to a 6-month-old male patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 05-Feb-2026, the patient started therapy with Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Inactivated Poliovirus (VAXELIS), Suspension for injection 0.5 mL (lot # and expiration date were not reported), Rotavirus Vaccine, Live, Oral, Pentavalent (Rotateq), Oral solution 2 mL (lot # and expiration date were not reported). And inadvertently also was vaccinated with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), Suspension for injection, dose number 1, 0.5 mL (lot # and expiration date were not reported) (inappropriate age at vaccine administration). All vaccines were administered as prophylaxis. No adverse event was reported. Lot numbers are being requested and will be submitted if received.